Summit Therapeutics Inc. (SMMT) Stock: Price, Forecast & Analyst Target
Summit Therapeutics Inc. (SMMT) — MoonshotScore 51/100 (Fair band), calculated Nov 18, 2026. Price $10.57 (+0.67%), as of the Nov 19, 2026 trading session; market cap $8.45B. Expected results Feb 22, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 13.42× (cash as of Sep 30, 2026) · expected results Feb 22, 2027
Summit Therapeutics Inc. · SMMT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Summit Therapeutics is a pre-revenue biopharmaceutical developer whose reported pipeline is concentrated in infectious-disease therapies, with ridinilazole as the flagship candidate for Clostridioides difficile infection. The case depends on whether clinical progress can produce a commercial asset before rising development spending consumes liquidity or prompts further financing.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Summit Therapeutics (SMMT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but weak quality, stalling growth and a full valuation. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 3 of the last 8 reports
- Altman Z 21.31 · Piotroski F 2
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 53 | Fair | |
| 53 | Fair | |
| 52 | Fair | |
| 52 | Fair | |
| 51 | Fair | |
| 51 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.57 | |
| Change on the day | +0.67% | |
| 52-week range | $10.53–$29.23 | |
| Market capitalisation | $8.45B | — |
| Price / earnings (trailing) | -19.78 | |
| Shares traded on the day | 9.01M | |
| Beta (volatility vs the S&P 500) | -1.52 |
Why Summit Therapeutics scores 51

Safety reads near the top, but growth is near the floor. That is typical of a clinical-stage drug developer.
Share price, last 12 months -22.3%
$20.04 $15.57
How the stock reacts to earnings
EPS beat in 4 of the last 12 reports (2023–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 12.1% either way.
- -16.3%Nov ’23
- -18.9%Feb ’24
- +3.3%May ’24
- -6.2%Aug ’24
- -14.8%Oct ’24
- -18.1%Feb ’25
- +15.7%May ’25
- -10.4%Aug ’25
- -10.7%Oct ’25
- +1.1%Feb ’26
- -22.7%Apr ’26
- -7.3%Jul ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Miss | — | -7.3% | -8.8% | |
| Beat | — | -22.7% | -17.7% | |
| Miss | — | +1.1% | +1.6% | |
| Miss | — | -10.7% | -7.3% | |
| Miss | — | -10.4% | -8.3% | |
| Beat | — | +15.7% | +2.2% | |
| Beat | — | -18.1% | -13.5% | |
| Miss | — | -14.8% | -4.3% | |
| Beat | — | -6.2% | +12.3% | |
| In line | — | +3.3% | +26.2% | |
| — | — | -18.9% | -13.2% | |
| — | — | -16.3% | -9.6% |
For a company without product revenue, earnings tell you little. Readouts from the lung cancer trials move this stock.
What management is saying differently
Management's own words on the Q2 FY2026 call () against Q4 FY2025 (). Analysts' questions are left out.
- New this call: “additional tumor”, “non-squamous cohorts” — none of them came up in Q4 FY2025.
- Getting louder: “statistically significant” (4 → 8 mentions), “global phase” (1 → 7 mentions), “iii studies” (2 → 7 mentions).
- Gone quiet: “interim pfs”, “final pfs”, “egfr mutant”, “primary endpoint” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.2 to 1.3 per 1,000 words, and confident words such as “record” and “strong” fell from 2.5 to 0.8.
Management sounded more assured, with new trial cohorts on the agenda.
Our track record on this stock
Since the score went from 47 to 51 while the share price moved -17.0% through .
The score has stayed in the Fair band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 65% of 23 rate it a buy; the average target sits +177.5% from the price of $10.57.
- Last 90 days: 3 upgrades and 0 downgrades among 11 rating actions.
- Our signals: Fair band; strongest pillar Financial Safety (95), weakest Growth Durability (10).
Analysts price a successful drug launch that our model has no way to score yet. Until revenue arrives, our reading stays cautious.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Summit Therapeutics (SMMT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Summit Therapeutics (SMMT), and what does it report?
Short answer · as of
Summit is developing therapies rather than selling an established drug portfolio.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Ridinilazole leads a pipeline aimed at bacterial infections, while other described programs target drug-resistant Enterobacteriaceae infections.
Current financial statements therefore measure development intensity and funding capacity, not product demand: recent periods show no revenue or gross profit, while research and administrative costs drive operating losses. Earlier revenue was classified as license and service revenue, so it should not be read as evidence of recurring product sales.
What do the latest results show for Summit Therapeutics (SMMT)?
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Research expense increased from the preceding period, administrative expense was nearly unchanged, and operating and net losses widened. The latest loss per share landed close to the prevailing estimate after the preceding report had been less negative than expected.
Operating cash use accelerated more sharply than the accounting loss changed. Cash still increased by period end, which means the balance-sheet improvement did not come from operations; the reported figures do not establish the external funding mechanism.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $169.13M Sep 30, 2026
- Latest quarter · SG&A
- $45.48M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$214.61M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | $169.13M | $45.48M | −$214.61M |
| Jun 30, 2026 | Not available | $157.73M | $62.76M | −$220.50M |
| Mar 31, 2026 | Not available | $132.62M | $62.59M | −$195.21M |
| Dec 31, 2025 | Not available | $147.29M | $77.58M | −$224.88M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue estimate
- $111,111 Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | Not available | $111,111 | −$0.2600 | −$0.2817 |
| Jul 23, 2026 | Not available | $113,889 | −$0.2800 | −$0.2744 |
| Apr 30, 2026 | Not available | $54,420 | −$0.2400 | −$0.3300 |
| Feb 23, 2026 | Not available | Provider row rejected | −$0.2900 | −$0.1026 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$208M | -$0.26 (diluted) |
| Jun 2026 | $0 | -$216M | -$0.28 (diluted) |
| Mar 2026 | $0 | -$189M | -$0.24 (diluted) |
| Dec 2025 | $0 | -$219M | -$0.29 (diluted) |
What are the financial strengths and risks for Summit Therapeutics (SMMT)?
Short answer · as of
Cash and short-term investments were $629.79M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$159.81M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Cash and short-term investments substantially exceed debt and total liabilities, while liquidity ratios indicate ample near-term coverage. The modeled runway extends beyond the immediate reporting calendar at the recent annualized cash-use rate.
That cushion is financing capacity, not business self-sufficiency. Operations consume cash, the burn rate has accelerated, and current revenue contributes nothing toward research spending. Net cash is also small beside the company’s market value, leaving valuation primarily exposed to pipeline outcomes rather than balance-sheet assets.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$159.81M Sep 30, 2026
- Previous quarter · operating cash flow
- −$167.78M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$159.81M | −$400,000 |
| Jun 30, 2026 | −$167.78M | −$970,000 |
| Mar 31, 2026 | −$122.29M | −$240,000 |
| Dec 31, 2025 | −$75.65M | −$120,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Summit Therapeutics (SMMT)?
Short answer · as of
The next earnings report is expected on Feb 22, 2027. The number it tests is the $-1.07 EPS analysts carry for it.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Research expense, operating cash use and the ending cash balance deserve to be read together. Continued burn acceleration without revenue would shorten the financing window even if reported debt remains modest.
Future revenue estimates assume a transition away from the current pre-revenue profile, but the later forecasts span an exceptionally wide range. Evidence of a recurring commercial revenue stream would matter more than a narrow earnings-per-share variance while development spending remains the dominant cost.
How does Summit Therapeutics compare with its peers?
Short answer
Summit Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Compared with a commercial biotechnology company, Summit currently has no product revenue, gross profit or operating cash generation to absorb development costs. Its accounts chiefly reveal how aggressively the pipeline is being funded and how much liquidity remains.
Compared with a diversified drug developer, Summit’s described pipeline is concentrated in bacterial infections, especially Clostridioides difficile and resistant Enterobacteriaceae. Low debt reduces creditor pressure, but concentrated clinical exposure and reliance on external capital make asset progress unusually important to the financial story.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| Summit Therapeutics (SMMT) — this page | $10.57 | $8.45B | 51 |
| $199.33 Nov 19, 2026 | $80.7B | 31 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $20.00 – $41.00
- Consensus target
- $33.13
- Median target
- $35.50
- Revenue estimate
- $2.37M
- EPS estimate
- $-1.07
Consensus record · Captured .
Measured against a quoted price of $10.57 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026
- Transactions
- 13
- Identified insiders
- 4
- Purchases
- 6
- Sales
- 0
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 17.3% Period end Sep 30, 2026
- Previous quarter · ownership
- 17.7% Prior to period end Sep 30, 2026
- Reporting holders
- 333 Period end Sep 30, 2026
- Previous quarter · holders
- 270 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Baker Bros. Advisors LP | 32,786,348 |
| Blackrock, INC. | 10,363,750 |
| Fmr LLC | 8,136,745 |
| Vanguard Capital Management LLC | 7,230,441 |
| Vanguard Portfolio Management LLC | 6,717,642 |
Tracked investors
Which of the 16 named investors we follow held SMMT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SMMT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Summit Therapeutics (SMMT)?
Summit Therapeutics Healthcare Stock: Key Questions Answered
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does ridinilazole mean for Summit Therapeutics?
Ridinilazole is the flagship candidate in Summit’s reported infectious-disease pipeline and is being developed as an oral treatment for Clostridioides difficile infection. Its importance is magnified because the company has no current revenue to diversify the economics.
Why does Summit Therapeutics report no revenue?
Summit is funding clinical development rather than reporting sales from an established commercial drug. Historical license and service revenue does not represent a current recurring product-sales base.
How exposed is Summit Therapeutics to rising research spending?
Research is the dominant operating expense and increased in the latest period, contributing to wider operating losses and heavier cash use. Without commercial revenue, that spending flows directly into the financing requirement.
Can Summit Therapeutics fund its infectious-disease pipeline?
Cash and short-term investments provide meaningful runway at the recent annualized burn rate, and debt is modest. Accelerating operating cash use means that runway must be reassessed as development intensity changes.
What is the SMMT stock price today?
The last price recorded for Summit Therapeutics Inc. (SMMT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SMMT price target?
The analyst consensus price target for Summit Therapeutics Inc. (SMMT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 68 figures on this page — 60 from Financial Modeling Prep (FMP), 5 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com